​​​Simplify Life​​® with Omnipod® 5

Get Started
Omnipod 5 Controller+ Pod+sensors_UK Omnipod 5 Controller+ Pod+sensors_UK
Screen is an example and for illustrative purposes only

The first and only tubeless automated insulin delivery system that works with the leading sensor brands*

Omnipod 5 is the first wearable, tubeless, hybrid closed loop insulin delivery system to integrate with the Dexcom G6 sensor and the FreeStyle Libre 2 Plus sensor**.

Omnipod 5 automatically adjusts insulin delivery every 5 minutes, helping to protect against highs and lows.1,2 It’s the​​ system that never sleeps.

What is Pod Therapy?

Pod Therapy is simple, tubeless, discreet insulin pump therapy for people living with type 1 diabetes, ages 2 and older.

Each wearable Pod continuously delivers personalised doses of insulin for up to three days (72 hours), controlled wirelessly by you, wherever you are.

With no multiple daily injections and no tubes, Pod Therapy is insulin pump therapy, simplified. Only found with Omnipod®.

Father and daughter doing homework together in the kitchen Father and daughter doing homework together in the kitchen
Omnipod 5 with Pod and no adhesive shown on a transparent background Omnipod 5 with Pod and no adhesive shown on a transparent background
Pod shown without necessary adhesive

Omnipod 5 Automated Insulin Delivery System

Now available with a choice of glucose sensor! Omnipod 5 automatically adjusts your insulin every five minutes, helping to stay in range throughout the day and night.

Omnipod DASH with Pod and without adhesive on a transparent background Omnipod DASH with Pod and without adhesive on a transparent background
Pod shown without necessary adhesive

Omnipod DASH® Insulin Management System

​​​You’re in control with the Omnipod DASH® Personal Diabetes Manager. Discover discreet, precise insulin dosing and customisable programmes designed to fit around your lifestyle.

Here’s what our Podders have to say about Omnipod…

Omnipod 5 has allowed me to get a good night sleep. That's the first time I can say that in a long time.

Alvin
Podder since 2017

It helps me feel like a normal kid, just with a little bit of help.

Romey T.
Sponsored Omnipod® User
& Podder since 2019

I don’t have to spend as much time thinking about diabetes.

Clare F.
Podder® since 2013

How can I find out more about the Omnipod?

We are delighted to have NordicInfu Care as our distributor in Norway. Please contact NordicInfu Care directly to learn how to get started on the Omnipod 5 or Omnipod DASH.

Address: Nordic Infucare AB, Tekniikantie 14, 02150 ESPOO
Phone: 0207 348 760
Email: [email protected]

Women having lunch at a cafe Women having lunch at a cafe
* Requires Dexcom G6 or FreeStyle Libre 2 Plus sensor. Bolus for meals and corrections are still needed.
**A separate prescription is required for the sensor. The Dexcom G6 and FreeStyle Libre 2 Plus sensors are sold separately.
† The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. Please see sensor manufacturer user guide for sensor waterproof rating‡ Fingerpricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021)
2. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose (>180mg/dL) from CGM in standard therapy vs Omnipod 5 = 39.4% vs. 29.5%. Average time with low blood glucose (<70mg/dL) from CGM in standard therapy vs Omnipod 5 = 3.41% vs. 2.13%. Sherr JL, et al. Diabetes Care (2022).